Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antifungal Ointment No. I is a topical combination drug designed to treat superficial fungal infections such as athlete's foot, jock itch, and tinea corporis. Its multi-component formulation includes sulfur, which acts as a keratolytic and antifungal agent by disrupting fungal cell components. Zinc oxide provides astringent, protective, and anti-inflammatory effects on the skin. For symptomatic relief, it contains diphenhydramine hydrochloride and dibucaine hydrochloride, both local anesthetics that alleviate itching and pain. Additionally, l-menthol offers a cooling sensation and mild anesthetic properties, while isopropylmethylphenol serves as an antiseptic to prevent secondary bacterial infections by disrupting microbial cell membranes. This combination aims to provide comprehensive treatment by targeting both the fungal pathogen and the associated discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Antifungal Ointment No. I.